NBP · Insider Trading
NovaBridge Biosciences American Depositary Shares
Every open-market purchase and sale reported by NBP officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-21 | Phillip Andrew Dennis | Chief Medical Officer | MIXED | +15,486 | −$5.83K |
| 2026-09-11 | Sean Wuxiong Cao | Chief Bus. Development Officer | Sell | −107,978 | −$79.90K |
| 2026-09-08 | Sean Wuxiong Cao | Chief Bus. Development Officer | M | +339,372 | — |
| 2026-09-01 | Cong Claire Xu | EVP, Clinical Development | MIXED | +6,100 | −$2.59K |
| 2026-08-25 | Robert A. Lenz | Director | M | +17,218 | — |
| 2026-07-10 | Mark Arnold Hagler | Chief Commercial Officer | A | +949,050 deriv. | — |
| 2026-07-10 | Liwei Lorraine Lin | General Counsel | A | +254,780 deriv. | — |
| 2026-07-08 | Srishti Gupta | Chief Executive Officer | A | +3,000,000 deriv. | — |
| 2026-07-07 | Cong Claire Xu | SVP, Clinical Development | MIXED | +7,947 | −$3.99K |
| 2026-06-24 | Sean Wuxiong Cao | Chief Bus. Development Officer | A | +362,570 deriv. | — |
| 2026-06-22 | Phillip Andrew Dennis | Chief Medical Officer | MIXED | +15,201 | −$5.61K |
| 2026-06-02 | Cong Claire Xu | SVP, Clinical Development | MIXED | +5,888 | −$13.77K |
| 2026-05-18 | Sean Wuxiong Cao | See Remarks | Sell | −21,399 | −$42.58K |
| 2026-04-28 | Mark Arnold Hagler | See Remarks | Buy | +230,000 | +$577.30K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Cong Claire Xu | EVP, Clinical Development | 304,201 | $424.36K |
| Sean Wuxiong Cao | Chief Bus. Development Officer | 266,467 | $371.72K |
| Mark Arnold Hagler | Chief Commercial Officer | 230,000 | $320.85K |
| Phillip Andrew Dennis | Chief Medical Officer | 173,427 | $241.93K |
| Robert A. Lenz | Director | 17,218 | $24.02K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the NBP quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.